Russell Greig is to be the new President, Pharmaceuticals International, of GlaxoSmithKline effective March 31, 2003. He will replace Howard Pien, who will move to Chiron Corporation, a global pharmaceutical company to become its chief executive officer and president.

Greig is currently senior vice president, Worldwide Business Development for R&D at GSK. In his new position as president he will report to David Stout, president, Pharmaceutical Operations. Greig will be based in London, and will become a member of the company's Corporate Executive Team.

Before assuming the role as head of Worldwide Business Development in R&D for GlaxoSmithKline in January 2000, Greig was a member of the merger Integration Team. He had been general manager and managing director, Pharmaceuticals UK, for SmithKline Beecham since December 1998, following a long-standing career in R&D. Greig joined the company in 1980, and holds a B.Sc. and Ph.D. in biochemistry from the University of Manchester.

In recognition of the increasing importance to GSK of the Japanese market, Marc Dunoyer, currently senior vice president and regional director, Japan, has been named president, Pharmaceuticals, Japan, also reporting to David Stout. Dunoyer will also join the Corporate Executive Team, and will continue to be based in Japan.

Marc Dunoyer joined Glaxo Wellcome in October 1999 as senior vice president, Glaxo Wellcome K.K. and was appointed to president & regional director, Japan, in March 2000. He previously worked for Hoechst Marion Roussel as president, Asia Pacific. Dunoyer has a Bachelor of Law degree from Paris University, and an MBA from the Hautes Etudes Commerciales.